Gershon A A
Am J Clin Pathol. 1978 Jul;70(1 Suppl):170-4.
A live attenuated varicella-zoster (V-Z) virus vaccine has been developed and tested by Dr. M. Takahashi and his colleagues in Japan. This vaccine appears to prevent varicella and is associated with minimal side effects even in patients at high risk to develop severe varicella. Antibody to V-Z virus appears after V-Z vaccination. This antibody has been detected by a variety of serologic technics, and it has been demonstrated to persist for as long as two years after vaccination. Thus far, V-Z vaccine has not been associated with subsequent zoster, but long-term studies will be required before this possibility can be ruled out.
一种减毒活水痘-带状疱疹（V-Z）病毒疫苗已由日本的高桥博士及其同事研发并进行了测试。这种疫苗似乎可以预防水痘，即使在有发生严重水痘高风险的患者中，其副作用也极小。接种V-Z疫苗后会出现V-Z病毒抗体。这种抗体已通过多种血清学技术检测到，并且已证明在接种疫苗后可持续长达两年。到目前为止，V-Z疫苗与随后发生的带状疱疹没有关联，但在排除这种可能性之前还需要进行长期研究。
